- BioNTech SE BNTX said it had signed a Memorandum of Understanding with the Rwandan government and Institut Pasteur de Dakar in Senegal to construct the first mRNA vaccine manufacturing facility in Africa starting in mid-2022.
- BioNTech will initially build a production line with 50 million doses annual capacity, which could be used for COVID-19 vaccines.
- The biotech firm added it would be branched out into a broader production network making several hundreds of million mRNA vaccine doses per year to transfer ownership and the know-how to local partners on the continent.
- In addition, BioNTech is in discussions about an expansion of the current partnership with Biovac, which is part of the Pfizer Inc PFE - BioNTech COVID-19 vaccine manufacturing network.
- Related: Pfizer/BioNTech Strike COVID-19 Manufacturing Deal With Biovac For South Africa.
- Price Action: BNTX shares closed 0.86% at $297.26 on Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: BiotechGovernmentNewsHealth CareContractsGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in